What`s new

Presentations.

Presentations

November 17th 2021

Immutep Global Webcast for AIPAC & TACTI-002 Data

Listen to the related webcast

November 12th 2021

SITC 2021 - AIPAC Poster

November 12th 2021

SITC 2021 - TACTI-003 Poster

November 12th 2021

SITC 2021 - TACTI-002 Poster

Click here for the poster with comments

November 10th 2021

SITC 2021 - AIPAC Abstract

November 10th 2021

SITC 2021 - TACTI-003 Abstract

November 10th 2021

SITC 2021 - TACTI-002 Abstract

September 27th 2021

Immutep Corporate Presentation September 2021

September 21st 2021

ESMO 2021 – INSIGHT (Stratum D) Poster

September 15th 2021

ASX Small & Mid Cap Conference - video presentation

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview.

July 26th 2021

2021 EGM Presentation

July 16th 2021

Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit - poster presentation

A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (prembrolizumab): results of a phase II study in NSCLC

June 21st 2021

Immutep Capital Raising Presentation

June 9th 2021

Immutep TACTI-002 and INSIGHT Clinical Results & Update Global Webcast Slides

Listen to the related webcast

June 4th 2021

ASCO 2021 - INSIGHT Poster

Listen to the related poster presentation

June 4th 2021

ASCO 2021 - TACTI-002 Poster for HNSCC

Listen to the related poster presentation

June 4th 2021

ASCO 2021 - TACTI-002 Poster for NSCLC

Listen to the related poster presentation

June 4th 2021

Immutep Presentation for Jefferies Healthcare Conference

May 13th 2021

Corporate Presentation

February 2nd 2021

Corporate Presentation

December 11th 2020

Immutep AIPAC Global Webcast Slides

Listen to the related webcast

December 10th 2020

SABCS 2020 - poster presentation

Primary efficacy results from AIPAC: A double blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG 3 protein) vs. weekly paclitaxel plus placebo in HR positive metastatic breast cancer patients

November 19th 2020

Immutep Investor Presentation

November 9th 2020

SITC 2020 - poster presentation

A Phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1
unselected patients with metastatic non-small cell lung (NSCLC) or head and neck carcinoma (HNSCC)

November 5th 2020

World Immunotherapy Congress 2020 - Updates to TACTI-002/ presentation of results of a phase II study in NSCLC and HNSCC

September 17th 2020

ESMO 2020 - TACTI-002 NSCLC Poster

September 17th 2020

ESMO 2020 - TACTI-002 HNSCC Poster

September 17th 2020

ESMO 2020 – INSIGHT-004 (Stratum D) Poster

September 17th 2020

ESMO 2020 – INSIGHT (Stratum A & B) Poster

September 8th 2020

ASX Small and Mid-Cap Virtual Conference – Presentation

Listen to the related webcast

July 9th 2020

Immutep CEO presentation BIO Asia-Taiwan

Listen to the related webcast

June 2nd 2020

Immutep TACTI-002 and INSIGHT Global Webcast Slides

Listen to the related webcast

May 29th 2020

ASCO 2020 - INSIGHT Poster

May 29th 2020

ASCO 2020 - TACTI-002 Poster

May 4th 2020

NWR Virtual Small Cap Health Conference Presentation

Listen to the related webcast

April 29th 2020

Immutep Investor Presentation

April 28th 2020

American Association for Cancer Research (AACR) Annual Meeting 2020 presentation of TACTI-002 interim data

Listen to related audio presentation

March 26th 2020

Immutep AIPAC Global Webcast Slides

Listen to the related webcast

February 25th 2020

Immutep TACTI-002 Clinical Results & Update Global Webcast Slides

Listen to the related webcast

February 19th 2020

German Cancer Congress presentation of TACTI-002 interim data

January 10th 2020

Corporate Presentation

December 12th 2019

San Antonio Breast Cancer Symposium - poster presentation of AIPAC (Active Immunotherapy PAClitaxel)

November 9th 2019

SITC 2019 - poster presentation of TACTI-002 interim data

November 2nd 2019

2019 AGM CEO Presentation

October 15th 2019

World Immunotherapy Congress 2019 presentation of TACTI-mel melanoma trial data

September 30th 2019

Corporate Presentation

June 26th 2019

Immutep KOL Event Presentation: A Novel IO Therapy (eftilagimodalpha) in Metastatic Breast Cancer and other settings

June 1st 2019

INSIGHT Trial - Poster - ASCO 2019

June 1st 2019

TACTI-002 (Two ACTive Immunotherapeutics) - Poster - ASCO 2019

May 22nd 2019

Corporate Presentation

May 17th 2019

Advanced Therapies and Regenerative Medicine London

April 2nd 2019

Immutep to Present Eftilagimod Alpha Clinical Development Update and New Data from Ongoing Melanoma Study

Listen to the related webcast: Update on Eftilagimod Alpha (IMP321)

March 25th 2019

Immutep to Present IMP761 Preclinical Results in Global Webcast

Listen to the related webcast: Immutep IMP761 Preclinical Results in Autoimmune Disease

March 8th 2019

Congress of European Crohn’s and Colitis Organisation (ECCO) Conference Presentation

March 6th 2019

World Immunotherapy Congress USA 2019 Presentation

February 25th 2019

Immutep Presentation to Emergence Conference

January 7th 2019

Corporate Presentation

November 27th 2018

4th Annual ICI Europe Summit Presentation

November 10th 2018

Oral Presentation - TACTI-mel - 33rd Annual Meeting SITC 2018, Washington, D.C., USA

November 10th 2018

Poster Presentation - TACTI-mel - 33rd Annual Meeting SITC 2018, Washington, D.C., USA

Results from a Phase I dose escalation trial (TACTImel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma

November 10th 2018

Poster Presentation - TACTI-002 - 33rd Annual Meeting SITC 2018, Washington, D.C., USA

A multicenter, phase II study in patients with first line NSCLC, or recurrent PD-X refractory NSCLC or with recurrent HNSCC receiving Eftilagimod Alpha in combination with Pembrolizumab (TACTI-002)

November 9th 2018

Corporate Investor Presentation

October 31st 2018

Presentation at World Immunotherapy Congress 2018, Basel, Switzerland

Two ACTive immunotherapies in melanoma (TACTI-mel):
results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab

October 30th 2018

Ausbiotech Presentation

October 29th 2018

Corporate Presentation

October 24th 2018

TACTI-mel Trial - Society for Melanoma Research Poster

October 3rd 2018

Presentation at Ladenburg Thalmann 2018 Healthcare Conference

Listen to the webcast “Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference”

Download "Ladenburg 2018 HC Conference Immutep Presentation"

September 7th 2018

Newsmakers Immutep Corporate Presentation

Listen to the webcast “Immutep Newsmakers Presentation”

Download "Newsmaker Immutep Corporate Presentation"

August 29th 2018

Corporate Investor Presentation

June 4th 2018

INSIGHT Trial - ASCO Poster

June 3rd 2018

AIPAC Trial In Progress - ASCO Poster

June 3rd 2018

AIPAC Safety Run-In - ASCO Poster

May 30th 2018

New Data from Ongoing Melanoma Study and Clinical Development Strategy Update (Webcast)

May 30th 2018

New Data from Ongoing Melanoma Study and Clinical Development Strategy Update

May 25th 2018

3rd Annual Advances in Immuno-Oncology Congress Presentation

May 17th 2018

Presentation at 13th Annual Advanced Therapy and Regenerative Medicine Congress 2018, London

LAG-3: the next immune checkpoint after CTLA-4 and PD-1/PDL-1?

May 17th 2018

Corporate Presentation

March 22nd 2018

Presentation at 3th Annual Immuno-Oncology Summit Europe, London

LAG-3: Identification & Validation Of Next Generation Checkpoint Pathway

January 5th 2018